DelveInsight’s “Celiac Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Celiac Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market Insights
Celiac Disease Overview
According to the World Gastroenterology Organization (WGO), celiac disease (CD) also known as coeliac disease/non-tropical sprue or gluten-sensitive enteropathy, is defined as a chronic, multiple-organ small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. It is a serious autoimmune disorder where the ingestion of gluten leads to damage in the small intestine; it is not an allergy caused by gluten.
Some of the key facts of the Celiac Disease Market Report:
- The Celiac Disease market size was valued USD 1,333.5 Million in the year 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to the Celiac Disease Foundation, celiac disease is considered as a serious autoimmune disease, which is estimated to affect 1 in 100 people worldwide
- The total prevalent population of Celiac Disease in the 7 MM was 6,450,607 in 2020 which is anticipated to increase during the Forecasted period (2022-32)
- Key Celiac Disease Companies: ImmunoGenX, 9 Meters Biopharma, Cour Pharmaceutical, Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, and others
- Key Celiac Disease Therapies: Latiglutenase (IMGX003), Larazotide Acetate, CNP-101, TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, and others
- The Celiac Disease epidemiology based on gender analyzed that females are affected more than males in case of Celiac Disease
Get a Free sample for the Celiac Disease Market Report-
https://www.delveinsight.com/sample-request/celiac-disease-cd-market
Key benefits of the Celiac Disease Market report:
- Celiac Disease market report covers a descriptive overview and comprehensive insight of the Celiac Disease Epidemiology and Celiac Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Celiac Disease market report provides insights on the current and emerging therapies.
- Celiac Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Celiac Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Celiac Disease market.
Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Epidemiological Insights
Celiac Disease Market
The dynamics of the Celiac Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Celiac Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Celiac Disease Epidemiology Segmentation:
The Celiac Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Celiac Disease
- Prevalent Cases of Celiac Disease by severity
- Gender-specific Prevalence of Celiac Disease
- Diagnosed Cases of Episodic and Chronic Celiac Disease
Celiac Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease market forecast
Celiac Disease Therapies and Key Companies
- Latiglutenase (IMGX003): ImmunoGenX
- Larazotide Acetate: 9 Meters Biopharma
- CNP-101/ TAK-101: Cour Pharmaceutical/ Takeda
- PRV-015 (AMG 714): Provention Bio
- ZED1227: Falk Pharma and Zedira
- AG017: Precigen ActoBio
- TAK-062: Takeda
Celiac Disease Market Drivers
- Robust Celiac Disease Pipeline Activity
- Increase in Awareness
- Increasing Prevalence and Diagnosed Prevalence in Europe
Scope of the Celiac Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Celiac Disease Companies: ImmunoGenX, 9 Meters Biopharma, Cour Pharmaceutical, Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, and others
- Key Celiac Disease Therapies: Latiglutenase (IMGX003), Larazotide Acetate, CNP-101, TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, and others
- Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
- Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Celiac Disease Unmet Needs, KOL’s views, Analyst’s views, Celiac Disease Market Access and Reimbursement
Celiac Disease Market Barriers
- Economic Burden on Patients
- Lack of Efficient Celiac Disease Diagnosis
- Differential Diagnosis
Table of Contents
1. Celiac Disease Market Report Introduction
2. Executive Summary for Celiac Disease
3. SWOT analysis of Celiac Disease
4. Celiac Disease Patient Share (%) Overview at a Glance
5. Celiac Disease Market Overview at a Glance
6. Celiac Disease Disease Background and Overview
7. Celiac Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Celiac Disease
9. Celiac Disease Current Treatment and Medical Practices
10. Celiac Disease Unmet Needs
11. Celiac Disease Emerging Therapies
12. Celiac Disease Market Outlook
13. Country-Wise Celiac Disease Market Analysis (2019–2032)
14. Celiac Disease Market Access and Reimbursement of Therapies
15. Celiac Disease Market Drivers
16. Celiac Disease Market Barriers
17. Celiac Disease Appendix
18. Celiac Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Celiac Disease treatment, visit @ Celiac Disease Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/